Glucosamine: From German Chitin Chemistry to the Joint Aisle

Glucosamine started as German chitin chemistry, not as a remedy. Ledderhose's 1880 paper is the earliest primary record here, GAIT found no overall pain benefit over placebo in 2006, and the Chinese and Japanese sources checked document no traditional joint use of shellfish, shell or shark cartilage.

Glucosamine started as a chemistry question about shell, not as a remedy, and the trial record behind the joint aisle is thinner than the shelf suggests. This post sets out the dated record, the trials and the official positions, and it says plainly where no documented use exists. The surprise comes first. In 1799, Hatchett treated crab, lobster, prawn and crayfish shells with mineral acid and reported that they went soft and "like a cartilage," as summarized by Crini's 2019 history of chitin ([DOI](https://doi.org/10.1007/978-3-030-16538-3_1)). Chitin is the material that makes shell tough. Chemists were working on it long before anyone wanted it in a capsule. **Jump to** - The short answer - Where the raw material comes from - The earliest records, Eastern first - Who isolated it, and when - Early products, patents and production - How the science changed - How the world has studied it - The global positions, side by side - What the evidence shows now - Why it is interesting - How to read a glucosamine label - Where Joint Solution fits - Bottom line - Frequently asked questions - Where the record is thin ## The short answer Glucosamine is an amino sugar. The 1914 English translation of Olof Hammarsten's textbook describes it as a derivative of glucose or mannose, probably glucose ([Hammarsten, via Project Runeberg](https://runeberg.org/physchem/0233.html)). Chemists first prepared it from chitin in German-language work of the 1870s and 1880s. The earliest primary record in this article is Georg Ledderhose's 1880 paper "Ueber Glykosamin." A 2019 chitin history by Crini dates Ledderhose's chitin work to 1876. There are two routes to the supplement ingredient today: chitin from crustacean shell, broken down with acid or enzymes, and microbial fermentation. The clinical record is a separate story. GAIT, a 2006 US trial, found that glucosamine alone was not significantly better than placebo for knee pain. European trials that reported slowed joint-space narrowing were published between 2001 and 2004. A 2010 network meta-analysis in the *BMJ* found no clinically important pain benefit overall. ## Where the raw material comes from Chitin is a long chain of sugar units. Crini's 2019 history says Braconnot identified it in fungi in 1811, and that Odier recognized a horn-like material from beetle wing cases in 1823 ([DOI](https://doi.org/10.1007/978-3-030-16538-3_1)). For supplements, the source that matters is crustacean shell. According to PubMed, a 2026 study in *Frontiers in Microbiology* calls chitin from shrimp and crab shells a primary resource for making glucosamine, and it says chemical hydrolysis is widely used in those processes ([DOI](https://doi.org/10.3389/fmicb.2026.1773725)). The traditional chemical method, as Hammarsten describes Ledderhose's preparation, uses concentrated hydrochloric acid. The enzyme alternative is newer. The same 2026 study reports a mangrove-derived enzyme mixture that hydrolyzed powdered chitin to about 70 percent within two hours at 65 degrees Celsius. It did so in a 40-liter working volume in 50-liter batch reactors, without an acid pretreatment step. That is a laboratory scale-up result, not a count of commercial output. The second route is fermentation. According to PubMed, a 2026 study in *Foods* engineered *Saccharomyces cerevisiae*, the baker's yeast, to make glucosamine. A triple knockout of pyruvate decarboxylase genes sent more carbon away from ethanol. The strain reached 2.20 grams per liter, a 1.54-fold gain over its parent, and its ethanol yield fell 26 percent ([DOI](https://doi.org/10.3390/foods15071163)). The authors call fermentation a sustainable alternative to the chemical route. Their yeast consumed glucose, so no shell was part of that process. ## The earliest records, Eastern first No Chinese or Japanese traditional text we have found documents a joint use of shellfish, shell or shark cartilage. The entries on aquatic animals and shellfish drugs in Li Shizhen's *Bencao Gangmu* (juan 45 and 46) describe them in general and name neither crab, oyster shell nor joints. Shark products carry traditional claims in some markets. According to PubMed, a 2014 toxicology study describes shark fin and cartilage products as marketed on traditional Chinese medicine claims that they nourish the blood, enhance appetite and energize internal organs ([DOI](https://doi.org/10.1016/j.fct.2014.04.015)). The three claims in that abstract concern blood, appetite and internal organs, not joints. A 2005 survey of Japanese cancer patients, also on PubMed, found that most of the complementary-medicine users among them used products such as mushrooms, herbs and shark cartilage ([DOI](https://doi.org/10.1200/JCO.2005.04.126)). That is modern use, and the survey records no joint purpose. The modern interest in shark cartilage began in a laboratory. In 1983, Lee and Langer reported that shark cartilage contains a substance that inhibits the growth of new blood vessels toward solid tumors, according to PubMed ([DOI](https://doi.org/10.1126/science.6193581)). In 2005, a randomized, placebo-controlled trial in 83 evaluable patients with advanced breast or colorectal cancer found no difference in overall survival with a shark cartilage product ([DOI](https://doi.org/10.1002/cncr.21107)). The earliest chitin observation cited in this article is Hatchett's 1799 account of shell. That is a chemistry date, not a medicine date, and the difference matters for any health claim built on the history. ## Who isolated it, and when The 1914 English translation of Hammarsten's textbook says glucosamine was "first prepared by Ledderhose from chitin by the action of concentrated hydrochloric acid" (page 219, [Project Runeberg scan](https://runeberg.org/physchem/0233.html)). Its footnotes cite volumes 2 and 4 of the *Zeitschrift für physiologische Chemie* for Ledderhose's work. The same passage notes that the compound is also called chitosamine, and that E. Fischer and Leuchs later showed it to be a derivative of glucose or mannose, probably glucose, citing volume 36 of the *Berichte der Deutschen Chemischen Gesellschaft*. A library record for Ledderhose's paper, "Ueber Glykosamin," gives 1880, volume 4 of the *Zeitschrift für Physiologische Chemie*, pages 139 to 159. The University of Regensburg's Virtual Laboratory hosts the item as open access ([record](https://vlp-new.ur.de/records/lit16357)). The 1880 paper is the earliest primary record here, and it is not necessarily the first isolation. Hammarsten cites an earlier volume of the same journal. Crini's 2019 history gives 1876 and describes Ledderhose hydrolyzing arthropod chitin ([DOI](https://doi.org/10.1007/978-3-030-16538-3_1)). The starting material is arthropod chitin in Crini's account. ## Early products, patents and production Patent records are the dated trail in this article. They show who was trying to make glucosamine salts for medicines, and when. They do not show when a product reached a pharmacy. - **1971 priority.** German patent DE2103387C3, "Use of the hydrochloride of glucosamine for the manufacture of pharmaceutical preparations," has a priority date of 26 January 1971. Its assignee is Johann G. W. Opfermann & Sohn of Bergisch-Gladbach, and the record shows publication on 6 May 1982 ([Google Patents](https://patents.google.com/patent/DE2103387C3/en)). - **1981 priority.** The Italian application IT67596/81A, dated 30 April 1981, is titled "Stable glucosamine sulphate compound, procedure for its preparation and pharmaceutical compositions containing such compound" ([Google Patents](https://patents.google.com/patent/IT1148050B/en)). - **1982 filing.** On 28 April 1982, German application DE3215844 was filed under the title "Mixed salt from glucosamine sulfate and sodium chloride." It was published on 2 December 1982. The applicant was Rotta Research Laboratorium S.p.A., and the current assignee is listed as Rottapharm SpA ([Google Patents](https://patents.google.com/patent/DE3215844A1/en)). A separate Rotta record places the company at San Fruttuoso di Monza, Milan ([Google Patents](https://patents.google.com/patent/DE2226273C2/en)). - **1982 family.** The same invention appears in a family of filings from April 1982. It covers Portugal, the United Kingdom, Switzerland, the Netherlands, Belgium, Greece, France, the United States and Japan. The US filing later appears as US 4,642,340 ([Google Patents](https://patents.google.com/patent/US4642340A/en)). The Japanese publication is dated 15 November 1982 ([Google Patents](https://patents.google.com/patent/JPS57185297A/en)). - **1989 grant.** The German patent's legal-status record shows the application granted on 3 August 1989. Two things stand out. The German family covers a mixed salt with sodium chloride. Some sulfate products are listed as salts with potassium chloride, as the product discussed below is, and salt forms are not interchangeable. Second, the trials behind the early evidence were concentrated in one product. The 2001 Cochrane review says most of the trials it reviewed evaluated the Rotta preparation of glucosamine sulfate ([DOI](https://doi.org/10.1002/14651858.CD002946)). **Production by country** **Japan.** NIBIOHN, a Japanese government research institute, runs a health food database. Its glucosamine entry says industrial glucosamine is made by breaking down chitin from crab and shrimp shell with hydrochloric acid. The same entry lists glucosamine hydrochloride as an existing food additive used as a thickener-stabilizer and processing aid ([NIBIOHN](https://hfnet.nibiohn.go.jp/contents/detail24.html)). **China.** According to PubMed, a 2013 review by authors at Jiangnan University in Wuxi, China, states that glucosamine is currently produced by acid hydrolysis of chitin extracted from crab and shrimp shells. The same review covers microbial production as an alternative ([DOI](https://doi.org/10.1007/s00253-013-4995-6)). That describes the production method. It does not give China's share of output or a dated history of its market. **Europe.** The European record is the patent trail above, which runs through Germany and Italy. It shows who sought protection for glucosamine salts and when. It does not show how much was made. ## How the science changed The clinical record moved in steps, and each step changed the question. The early trials measured joint-space width on X-rays over three years. The largest later trials measured pain over a few months. Meta-analyses then argued over which trials counted. - **1980.** Crolle and D'Este published a randomized controlled trial of glucosamine sulphate for arthrosis in *Current Medical Research and Opinion*. According to PubMed, the record has no abstract ([DOI](https://doi.org/10.1185/03007998009112035)). - **2001, Cochrane.** The Cochrane review of glucosamine for osteoarthritis pooled 16 trials and concluded that glucosamine was "both effective and safe." According to PubMed, the review also noted that most of its trials tested the Rotta preparation ([DOI](https://doi.org/10.1002/14651858.CD002946)). - **2001, Lancet.** Reginster and colleagues ran a three-year trial of 212 people with knee osteoarthritis. Joint-space loss was -0.31 mm on placebo (95% CI -0.48 to -0.13) and -0.06 mm on glucosamine sulphate, with no significant loss on glucosamine (95% CI -0.22 to 0.09). Symptoms worsened slightly on placebo and improved on glucosamine. The authors suggested the drug could be a disease-modifying agent ([DOI](https://doi.org/10.1016/S0140-6736(00)03610-2)). - **2002, Archives of Internal Medicine.** Pavelka and colleagues randomized 202 people to glucosamine sulfate, 1,500 mg a day, or placebo for three years. Placebo lost 0.19 mm of joint space. Glucosamine showed no average change, a significant difference (P=.001). Severe narrowing occurred in 5 percent of glucosamine patients and 14 percent of placebo patients (P=.05) ([DOI](https://doi.org/10.1001/archinte.162.18.2113)). - **2004, Menopause.** Bruyère and colleagues pooled two three-year trials. In a post hoc analysis of 319 postmenopausal women, joint space showed no narrowing on glucosamine (+0.003 mm) and narrowed by 0.33 mm on placebo. The authors described a disease-modifying effect in that group. It was a subgroup analysis, not the planned primary result ([DOI](https://doi.org/10.1097/01.gme.0000087983.28957.5d)). - **2005, Cochrane update.** The updated review pooled 20 trials and 2,570 patients. Its pooled results favored glucosamine, but the analysis restricted to studies with adequate allocation concealment found no benefit for pain or WOMAC function. The benefit concentrated in trials of the Rotta preparation, with a pooled pain effect of -1.31 standardized mean differences (95% CI -1.99 to -0.64) across 10 trials. Trials of other preparations did not reach significance for pain ([DOI](https://doi.org/10.1002/14651858.CD002946.pub2)). The pattern is worth noticing. The early trials measured structure on X-rays. The later large trials measured pain on a scale over a short window. The meta-analyses then disagreed about whether the product, the trial design or the funding explained the spread. ## How the world has studied it The sections below cover the United States, Europe, Germany, Japan, the United Kingdom, China and India. The table that follows puts the official positions side by side. **United States.** GAIT, a 24-week trial of 1,583 people, is the best-known US study. According to PubMed, it is indexed as NIH extramural research support ([DOI](https://doi.org/10.1056/NEJMoa052771)). NCCIH, the NIH's complementary health center, summarizes the US guidelines in its fact sheet. The Japanese translation on the eJIM site reports that the 2019 ACR/AF and OARSI guidelines advise against glucosamine for knee osteoarthritis ([eJIM](https://www.ejim.mhlw.go.jp/pro/overseas/c03/21.html)). **Europe.** The European trials cited above have first authors in Belgium (Reginster and Bruyère) and the Czech Republic (Pavelka), according to PubMed affiliation records. The European Food Safety Authority's 2012 opinion on joint cartilage is in the table. The 2010 network meta-analysis in the *BMJ* was led from the University of Bern in Switzerland ([DOI](https://doi.org/10.1136/bmj.c4675)). The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) recommends prescription crystalline glucosamine sulfate for knee osteoarthritis, and it does not recommend other glucosamine preparations, according to the NCCIH summary on eJIM. **Germany.** The German record runs through patents and a federal risk assessment. The patents from 1971 to 1989 are covered above. On 23 February 2012, the Federal Institute for Risk Assessment (BfR) published a press release warning that glucosamine in food supplements carries a risk for patients who take coumarin anticoagulants. The release says the European Food Safety Authority confirmed the BfR risk assessment ([BfR](https://www.bfr.bund.de/presseinformation/glucosamin-in-nahrungsergaenzungsmitteln-riskant-auch-fuer-patienten-die-cumarin-antikoagulanzien-einnehmen/)). **Japan.** NIBIOHN's health food database classifies glucosamine hydrochloride as a food ingredient, not a drug, unless a product makes drug-type efficacy claims ([NIBIOHN](https://hfnet.nibiohn.go.jp/contents/detail24.html)). Its efficacy summary says glucosamine sulfate is probably effective for osteoarthritis, and it finds no effect for relieving severe, long-term osteoarthritis pain. The entry's reference list runs to 2018. The 2018 meta-analysis by Japanese authors is covered in the table ([DOI](https://doi.org/10.1007/s10067-018-4106-2)). **United Kingdom.** The NHS prescribing briefing from PrescQIPP, dated November 2017, reports NICE's 2014 osteoarthritis guideline (CG177). According to the briefing, when a person presents with osteoarthritis, clinicians should not prescribe chondroitin or glucosamine products. The briefing says glucosamine, with or without chondroitin, is not recommended for NHS prescribing, and that new prescriptions should not start. It also reports that the Medicines and Healthcare products Regulatory Agency warned in 2006 against glucosamine use by people with seafood allergies or those taking warfarin ([PrescQIPP briefing](https://nhsdorset.nhs.uk/medicines/wp-content/uploads/sites/3/2022/09/Glucosamine-briefing.pdf)). **China.** Two recent trials are the most current Chinese clinical work in this article. A 2025 randomized trial of 60 patients from a Guangdong hospital compared glucosamine hydrochloride with eperisone added, both alongside exercise. The add-on arm had lower inflammatory markers and better scores ([DOI](https://doi.org/10.1080/1061186X.2025.2573055)). A 2026 Chinese-language trial of 62 patients used glucosamine hydrochloride tablets as part of treatment and added a herbal granule in one arm, with a cartilage-injury marker panel ([DOI](https://doi.org/10.12122/j.issn.1673-4254.2026.05.06)). Both are add-on designs, so neither separates glucosamine's own effect. **India.** A 2004 randomized, double-blind, placebo-controlled trial at the Nizam's Institute of Medical Sciences in Hyderabad tested oral glucosamine, 500 mg three times a day, against MSM, a combination and placebo in 118 patients for 12 weeks. According to PubMed, the authors report that glucosamine significantly improved the pain index compared with placebo ([DOI](https://doi.org/10.2165/00044011-200424060-00005)). ## The global positions, side by side Each row gives what the body said and when. The bodies are listed, not ranked. | Body or study | Year | What it said | Source | |---|---|---|---| | EFSA scientific panel (EU), claim on maintaining normal joint cartilage | 2012 | No cause-and-effect relationship established for people without osteoarthritis; no human studies provided for that group | [EFSA Journal 2691](https://efsa.europa.eu/en/efsajournal/pub/2691) | | BfR (Germany), glucosamine supplements and coumarin anticoagulants | 2012 (press release, 23 February) | Patients taking coumarin anticoagulants face added risk from glucosamine-containing supplements; EFSA confirmed the BfR risk assessment | [BfR](https://www.bfr.bund.de/presseinformation/glucosamin-in-nahrungsergaenzungsmitteln-riskant-auch-fuer-patienten-die-cumarin-antikoagulanzien-einnehmen/) | | NICE (UK), osteoarthritis guideline CG177, as reported by PrescQIPP | 2014 (briefing 2017) | Do not prescribe chondroitin or glucosamine products when a person presents with osteoarthritis | [PrescQIPP briefing](https://nhsdorset.nhs.uk/medicines/wp-content/uploads/sites/3/2022/09/Glucosamine-briefing.pdf) | | NIBIOHN (Japan), health food database | Entry's references run to 2018 | Glucosamine hydrochloride treated as a food ingredient unless drug claims are made; sulfate probably effective for osteoarthritis, not for severe long-term pain | [NIBIOHN](https://hfnet.nibiohn.go.jp/contents/detail24.html) | | American College of Rheumatology and Arthritis Foundation (US), as summarized by NCCIH | 2019 | Advises against glucosamine alone or with chondroitin for knee osteoarthritis; conditional recommendation for chondroitin in hand osteoarthritis | [eJIM copy of NCCIH](https://www.ejim.mhlw.go.jp/pro/overseas/c03/21.html); [DOI](https://doi.org/10.1002/acr.24131) | | OARSI (international), as summarized by NCCIH | 2019 | Strongly recommends against glucosamine for knee osteoarthritis, citing lack of efficacy | [eJIM copy of NCCIH](https://www.ejim.mhlw.go.jp/pro/overseas/c03/21.html); [DOI](https://doi.org/10.1016/j.joca.2019.06.011) | | AAOS (US), as summarized by NCCIH | 2021 | Lists glucosamine among supplements that may help mild-to-moderate knee osteoarthritis, while noting inconsistent evidence | [eJIM copy of NCCIH](https://www.ejim.mhlw.go.jp/pro/overseas/c03/21.html) | | ESCEO (Europe), as summarized by NCCIH | 2019 | Strongly recommends prescription crystalline glucosamine sulfate for knee osteoarthritis; does not recommend other preparations | [eJIM copy of NCCIH](https://www.ejim.mhlw.go.jp/pro/overseas/c03/21.html) | | Wandel et al. (Switzerland-led meta-analysis, BMJ) | 2010 | Pain difference of -0.4 cm on a 10 cm scale, short of the -0.9 cm clinically important threshold; joint-space differences tiny; authors say insurers should not cover | [DOI](https://doi.org/10.1136/bmj.c4675) | | Towheed et al. (Cochrane review) | 2001 and 2005 | 2001: effective and safe. 2005: benefit concentrated in the Rotta preparation; restricted analysis showed no benefit for pain | [DOI](https://doi.org/10.1002/14651858.CD002946.pub2) | | Ogata et al. (Japan, meta-analysis) | 2018 | Marginal pain benefit; WOMAC function not significant; small Japanese-measure subset favored glucosamine | [DOI](https://doi.org/10.1007/s10067-018-4106-2) | | GAIT (US, NIH extramural support) | 2006 | Glucosamine not significantly better than placebo; combination benefit in a moderate-to-severe subgroup was exploratory | [DOI](https://doi.org/10.1056/NEJMoa052771) | Where these bodies agree, glucosamine's pain benefit is small once weaker trials are set aside, and none of the rows recommends glucosamine for joint structure. Where they disagree, the 2001 Cochrane review and the European joint-space trials read positive, while the 2005 restricted Cochrane analysis and GAIT read flat on pain. The 2010 analysis found a difference below its clinical threshold. The split tracks two things: which product was tested, and which trials an analyst counts. The US and UK guideline bodies advise against glucosamine. The Japanese database calls the sulfate form probably effective for osteoarthritis, and the AAOS and ESCEO entries are narrower or mixed. We do not rank these bodies against each other, because each answered a different question with different evidence. ## What the evidence shows now GAIT is the study to read first. It randomized 1,583 people with symptomatic knee osteoarthritis to glucosamine (1,500 mg a day), chondroitin sulfate (1,200 mg a day), both, celecoxib (200 mg a day) or placebo for 24 weeks, according to the [NEJM record](https://doi.org/10.1056/NEJMoa052771). The primary outcome was a 20 percent drop in knee pain from baseline. The placebo response was 60.1 percent. Glucosamine added 3.9 percentage points (P=0.30), chondroitin added 5.3 (P=0.17), and the combination added 6.5 (P=0.09). The celecoxib arm, included as an active comparator, added 10.0 points (P=0.008). Among the 354 people with moderate-to-severe pain at the start, 79.2 percent of the combination group responded, against 54.3 percent on placebo (P=0.002). The authors labeled that subgroup finding exploratory. Adverse events were mild, infrequent and evenly spread across the groups. The 2010 meta-analysis in the *BMJ* pooled 10 trials and 3,803 patients. On a 10-centimeter pain scale, glucosamine's difference from placebo was -0.4 cm (95% credible interval -0.7 to -0.1). None of the estimates reached the -0.9 cm threshold the authors had set as clinically important. Joint-space differences were tiny, with intervals overlapping zero. Trials funded by industry showed larger effects than independent trials (P=0.02 for the interaction). The authors concluded that health authorities and insurers should not cover these preparations ([DOI](https://doi.org/10.1136/bmj.c4675)). Put plainly, the pain effect is small or unproven once the weaker trials are set aside. The European trials reported slowed joint-space narrowing, but the 2010 analysis found joint-space differences that overlapped zero. EFSA found no established cause and effect for people without osteoarthritis. Three limits matter as well. The 2001 Cochrane review did not settle the question, because its 2005 update narrowed it. The European results do not apply to every glucosamine product, since the Cochrane analysis points to one preparation. And a label that says glucosamine does not tell you which form, salt or source was tested. ## Why it is interesting The chain is unusual. The tough material in shell was first noticed in 1799. German chemists split a sugar out of it in the 1870s and 1880s, and that sugar is now also made by fermenting yeast. Each step changed the raw material, and each step left a patent or a paper behind. Another reason is that the trial record is product-specific. The 2005 Cochrane analysis found the benefit concentrated in one preparation, which is a warning about treating "glucosamine" as one thing. The German patent family for a mixed sulfate salt shows the same point from the manufacturing side: the form of the molecule is part of the product. ## How to read a glucosamine label Glucosamine is a cartilage question, not a bone question. If your question is bone, our [vitamin D guide](/health/vitamin-d-complete-guide) covers that separately. For the wider glucosamine and chondroitin picture, see [Exploring the Glucosamine Chondroitin Benefits of Supplements](/blog/bone-joint-support/exploring-the-glucosamine-chondroitin-benefits-of-supplements). Four checks apply to any glucosamine product, in this order: - **The salt form.** Glucosamine hydrochloride and glucosamine sulfate are different forms with different milligram totals. Some sulfate products are listed as salts with potassium chloride or sodium chloride, and the German patent family covers a mixed sodium chloride salt. Read the exact form on the label. - **Milligrams per serving.** A blend's total weight tells you less than the amount of each form. - **Servings and price per day.** Divide the price by the servings, then by how many servings you take each day. That is the number to compare. - **The source line.** Many labels name the shell source, such as crab or shrimp. NIBIOHN notes that crustacean-derived products can trigger reactions in people with crustacean allergy, and that manufacturing processes and quality standards vary from company to company. If you avoid shellfish, read that line and ask your clinician before you start. Safety notes travel with the source line. NCCIH's summary, carried on Japan's eJIM site, says glucosamine can raise blood sugar in some people, and that glucosamine taken with chondroitin has been linked to a higher bleeding risk in people taking warfarin ([eJIM](https://www.ejim.mhlw.go.jp/pro/overseas/c03/21.html)). The German and British warnings above point the same way. ## Where Joint Solution fits Joint Solution with Glucosamine, from Mt. Angel Vitamins, is the one product this article discusses. Its label lists 750 mg of glucosamine HCl and 250 mg of glucosamine sulfate per four-capsule serving. The sulfate is listed as 332 mg of glucosamine sulfate KCl, and both forms are labeled as isolated from crab shell. The serving also lists Boswellia serrata extract, bromelain, quercetin, Curcumin C3 Complex, devil's claw, alfalfa, collagen type II and yucca root. The bottle holds 60 capsules, or 15 servings, and the directions read "one to two capsules twice daily." The label says the product supports joint structure and joint comfort. The product page says independent ISO 17025 labs test each lot, and that every lot has its own certificate of analysis. Price per day, as listed on 20 October 2026: the bottle is $21.99, or $1.47 per four-capsule serving. At the top of the directions, two capsules twice daily, that is one serving a day, about $1.47, with 1,000 mg of labeled glucosamine. At the bottom, one capsule twice daily, it is half a serving, about $0.73. The GAIT trial used 1,500 mg of glucosamine a day, so the top of these directions gives about two-thirds of that amount. The GAIT abstract does not name the salt form it used, so this article does not compare forms. [Joint Solution with Glucosamine: current label and price](https://mtangelvitamins.com/products/joint-support-structure-and-comfort?utm_source=learn_hub&utm_medium=content&utm_campaign=blog_post&utm_content=history-of-glucosamine-from-shellfish-to-joint-supplement) ## Bottom line If you want the evidence before the bottle, the honest read is that glucosamine's benefit is small, depends on which product was tested, and is still disputed among researchers and regulators. Judge any glucosamine product against a controlled-trial timeline, which in GAIT was 24 weeks, not against a few days of use. Read the salt form, the milligrams per serving and the source line before you compare prices. If hyaluronic acid is the other joint ingredient you are weighing, read [Uncovering the Truth About Hyaluronic Acid](/blog/bone-joint-support/uncovering-the-truth-about-hyaluronic-acid-benefits-side-effects-and-dosage). ## Frequently asked questions ### Who first isolated glucosamine, and from what? Georg Ledderhose prepared it from chitin using concentrated hydrochloric acid, according to the 1914 English translation of Hammarsten's textbook. The earliest primary record in this article is his 1880 paper "Ueber Glykosamin," in volume 4 of the *Zeitschrift für Physiologische Chemie*. A 2019 chitin history dates the chitin work to 1876 ([DOI](https://doi.org/10.1007/978-3-030-16538-3_1)). ### What are the routes to supplement glucosamine? Two routes are documented in the sources cited here. One breaks chitin from crustacean shell down with acid or enzymes. The other uses engineered yeast to make glucosamine from sugar, which a 2026 study shows in the laboratory ([DOI](https://doi.org/10.3390/foods15071163)). Each route starts from a different raw material, so the source line on a label matters. ### When did glucosamine move from European pharmacies into US supplements? The dated record here runs through European patents. A German application filed in April 1982 covers a glucosamine sulfate and sodium chloride salt, and Google Patents shows it granted on 3 August 1989. The record cited here has no dated entry for the first US supplement. ### What did the early glucosamine trials try to measure? Mostly joint-space width on X-rays, plus symptom scores. Reginster and colleagues (2001) and Pavelka and colleagues (2002) measured joint-space narrowing over three years. GAIT, in 2006, used a different main measure: a 20 percent drop in knee pain over 24 weeks. ### What did the 2006 GAIT trial find? GAIT randomized 1,583 people with knee osteoarthritis to glucosamine, chondroitin, both, celecoxib or placebo for 24 weeks. None of the supplement arms was significantly better than placebo on the main measure. Glucosamine added 3.9 percentage points (P=0.30). A moderate-to-severe subgroup did better on the combination, 79.2 percent against 54.3 percent on placebo, but the authors called that analysis exploratory ([DOI](https://doi.org/10.1056/NEJMoa052771)). ### How do shellfish-derived and fermentation-derived glucosamine differ? They start from different materials and reach glucosamine by different steps. Shell-derived material begins with chitin from crab or shrimp shell, which acid or enzymes break into sugar units. Fermentation-derived material begins with sugar, which engineered yeast converts to glucosamine. No head-to-head clinical comparison of the two appears in the sources cited here, so do not assume they behave the same in the body. If you avoid shellfish, read the source line and ask your clinician before use. **Next reads** - [Exploring the Glucosamine Chondroitin Benefits of Supplements](/blog/bone-joint-support/exploring-the-glucosamine-chondroitin-benefits-of-supplements): the wider glucosamine and chondroitin picture, if you want the supplement side in more detail. - [Uncovering the Truth About Hyaluronic Acid](/blog/bone-joint-support/uncovering-the-truth-about-hyaluronic-acid-benefits-side-effects-and-dosage): the other joint ingredient people compare with glucosamine. ## Where the record is thin The 1876 date appears only in Crini's 2019 history, and no primary record for that year is cited here. The decades between 1880 and the 1970s are thin in the sources cited here. The 2001 Cochrane review noted that most of its trials tested the Rotta preparation, so the trial record for other salts and sources is thinner. No head-to-head clinical comparison of shellfish-derived and fermentation-derived glucosamine appears in the sources cited here. ### Related reading - [Collagen: from boiled bones to hydrolyzed peptides](/blog/history/history-of-collagen-from-boiled-bones-to-peptides) - [Turmeric and curcumin: from traditional spice to the capsule](/blog/history/history-of-turmeric-and-curcumin-from-ayurveda-to-isolation) - [Cod liver oil and the marine omega-3 story](/blog/history/history-of-omega-3-from-cod-liver-oil-to-epa-and-dha)